{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:03:51Z","timestamp":1791313431326,"version":"4.3.1"},"reference-count":192,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejphar.2021.173890","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T02:15:35Z","timestamp":1611108935000},"page":"173890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"special_numbering":"C","title":["A review of potential suggested drugs for coronavirus disease (COVID-19) treatment"],"prefix":"10.1016","volume":"895","author":[{"given":"Parastoo","family":"Tarighi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samane","family":"Eftekhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Chizari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Sabernavaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davod","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo","family":"Mirzabeigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.173890_bib1","unstructured":"A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04320615."},{"key":"10.1016\/j.ejphar.2021.173890_bib2","doi-asserted-by":"crossref","first-page":"101615","DOI":"10.1016\/j.tmaid.2020.101615","article-title":"Remdesivir as a possible therapeutic option for the COVID-19","volume":"34","author":"Al-Tawfiq","year":"2020","journal-title":"Trav. Med. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ejphar.2021.173890_bib3","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al\u2010Bari","year":"2017","journal-title":"Pharma Res Per"},{"key":"10.1016\/j.ejphar.2021.173890_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.micpath.2020.104228","article-title":"In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect","volume":"145","author":"Andreani","year":"2020","journal-title":"Microb. Pathog."},{"issue":"2","key":"10.1016\/j.ejphar.2021.173890_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02425-17","article-title":"Mechanism of darunavir (DRV)\u2019s high genetic barrier to HIV-1 resistance: a key V32I substitution in protease rarely occurs, but once it occurs, it predisposes HIV-1 to develop DRV resistance","volume":"9","author":"Aoki","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.ejphar.2021.173890_bib6","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/annrheumdis-2020-217706","article-title":"Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series","volume":"79","author":"Aouba","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2021.173890_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105944","article-title":"Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19","volume":"55","author":"Baron","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2021.173890_bib8","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","article-title":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model","volume":"18","author":"Beck","year":"2020","journal-title":"Comput Sstruct Biotechnol"},{"key":"10.1016\/j.ejphar.2021.173890_bib9","unstructured":"Bevacizumab in Severe or Critically Severe Patients with COVID-19 Pneumonia-RCT (BEST-RCT). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04305106."},{"key":"10.1016\/j.ejphar.2021.173890_bib10","unstructured":"Bevacizumab in severe or critical patients with CoVID-19 pneumonia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04275414?term=NCT04275414&draw=2&rank=1."},{"key":"10.1016\/j.ejphar.2021.173890_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.antiviral.2013.08.008","article-title":"Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking","volume":"100","author":"Blaising","year":"2013","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejphar.2021.173890_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2021.173890_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/ph13030051","article-title":"Emetine, Ipecac, Ipecac alkaloids and analogues as potential antiviral agents for coronaviruses","volume":"13","author":"Bleasel","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2021.173890_bib14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2165\/00003495-199447050-00008","article-title":"Teicoplanin: a reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy","volume":"47","author":"Brogden","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2021.173890_bib15","doi-asserted-by":"crossref","first-page":"102969","DOI":"10.1016\/j.ebiom.2020.102969","article-title":"Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients","volume":"59","author":"Buijsers","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejphar.2021.173890_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.ejphar.2021.173890_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2021.173890_bib18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s13063-020-04352-9","article-title":"Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe pneumonia caused by COVID-19 virus infection: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial","volume":"21","author":"Cao","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.ejphar.2021.173890_bib19","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2021.173890_bib20","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19","author":"Cavalcanti","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2021.173890_bib21","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"The Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.ejphar.2021.173890_bib22","doi-asserted-by":"crossref","first-page":"106029","DOI":"10.1016\/j.ijantimicag.2020.106029","article-title":"Is Teicoplanin A complementary treatment option for Covid-19? The question remains","volume":"56","author":"Ceccarelli","year":"2020","journal-title":"Int J Antimicrob"},{"key":"10.1016\/j.ejphar.2021.173890_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.chest.2020.10.009","article-title":"Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019","volume":"159","author":"Cepelowicz Rajter","year":"2020","journal-title":"CHEST J."},{"key":"10.1016\/j.ejphar.2021.173890_bib24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00284-001-0016-6","article-title":"Inhibition of 50S ribosomal subunit assembly in Haemophilus influenzae cells by azithromycin and erythromycin","volume":"44","author":"Champney","year":"2002","journal-title":"Curr. Microbiol."},{"issue":"3","key":"10.1016\/j.ejphar.2021.173890_bib25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19","volume":"384","author":"Chen","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2021.173890_bib26","series-title":"Favipiravir Versus Arbidol for COVID-19: A Randomized Clinical Trial","author":"Chen","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib27","series-title":"Thalidomide combined with Low-dose Glucocorticoid in the Treatment of COVID-19 Pneumonia","author":"Chen","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib28","series-title":"Efficacy of Hydroxychloroquine in Patients with COVID-19: results of a Randomized Clinical Trial","author":"Chen","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib29","series-title":"The QT Interval in Patients with SARS-CoV-2 Infection treated with Hydroxychloroquine\/Azithromycin","author":"Chorin","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib30","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2021.173890_bib31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(03)13973-6","article-title":"Treatment of SARS with human interferons","volume":"362","author":"Cinatl","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2021.173890_bib32","unstructured":"Clinical trials for ivermectin AND covid-19. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=ivermectin+AND+covid-19."},{"key":"10.1016\/j.ejphar.2021.173890_bib34","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.2174\/0929867327666200416131117","article-title":"SARS CoV-2: recent reports on antiviral therapies based on lopinavir\/ritonavir, darunavir\/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus","volume":"27","author":"Costanzo","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2021.173890_bib35","unstructured":"Covid 19 Ivermectin. 2020. https:\/\/clinicaltrials.gov\/ct2\/results?term=ivermectin&recrs=abcdefghl&cond=covid19.."},{"key":"10.1016\/j.ejphar.2021.173890_bib36","first-page":"786","article-title":"Rapid and severe covid-19 pneumonia with severe acute chest syndrome in a Sickle cell patient successfully treated with tocilizumab","volume":"95","author":"De Luna","year":"2020","journal-title":"Am Jur Hematol"},{"key":"10.1016\/j.ejphar.2021.173890_bib37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijid.2020.05.085","article-title":"Lack of antiviral activity of darunavir against SARS-CoV-2","volume":"97","author":"De Meyer","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejphar.2021.173890_bib38","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"De Wilde","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2021.173890_bib39","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1136\/annrheumdis-2020-218122","article-title":"Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study","volume":"79","author":"Della-Torre","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2021.173890_bib40","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/jmv.25897","article-title":"Off\u2010label use of tocilizumab in patients with SARS\u2010CoV\u20102 infection","volume":"92","author":"Di Giambenedetto","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejphar.2021.173890_bib41","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","article-title":"Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic","volume":"75","author":"Driggin","year":"2020","journal-title":"J Am. Col. Cardiol."},{"key":"10.1016\/j.ejphar.2021.173890_bib42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.1844","article-title":"Favipiravir: pharmacokinetics and concerns about clinical trials for 2019\u2010nCoV infection","volume":"108","author":"Du","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2021.173890_bib43","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2021.173890_bib44","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1007\/s11606-020-06146-w","article-title":"Chloroquine and hydroxychloroquine for the treatment of COVID-19: a systematic review and meta-analysis","volume":"35","author":"Elavarasi","year":"2020","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.ejphar.2021.173890_bib45","doi-asserted-by":"crossref","first-page":"117477","DOI":"10.1016\/j.lfs.2020.117477","article-title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19","volume":"248","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2021.173890_bib46","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/17512433.2016.1182425","article-title":"Icatibant as acute treatment for hereditary angioedema in adults","volume":"9","author":"Farkas","year":"2016","journal-title":"Expet Rev. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.ejphar.2021.173890_bib47","doi-asserted-by":"crossref","DOI":"10.1089\/jir.2020.0105","article-title":"Impact of hydroxychloroquine\/chloroquine in COVID-19 therapy: two sides of the coin","volume":"40","author":"Fatima","year":"2020","journal-title":"Interferon Cytokine Res"},{"key":"10.1016\/j.ejphar.2021.173890_bib48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.thromres.2020.06.027","article-title":"Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review","volume":"194","author":"Fletcher-Sandersj\u00f6\u00f6","year":"2020","journal-title":"Tromb Res"},{"key":"10.1016\/j.ejphar.2021.173890_bib49","series-title":"Fact sheet for Healthcare Providers: emergency Use Authorization (EUA) of Bamlanivimab","author":"Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib50","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"The Lancet."},{"key":"10.1016\/j.ejphar.2021.173890_bib51","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12250-020-00207-4","article-title":"Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools","volume":"35","author":"Fu","year":"2020","journal-title":"Virol. Sin."},{"key":"10.1016\/j.ejphar.2021.173890_bib52","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(20)31862-6","article-title":"Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial","volume":"396","author":"Furtado","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2021.173890_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","author":"Garcia","year":"2020","journal-title":"Canc. Treat Rev."},{"key":"10.1016\/j.ejphar.2021.173890_bib54","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2021.173890_bib55","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study","volume":"34","author":"Gautret","year":"2020","journal-title":"Trav. Med. Infect. Dis."},{"key":"10.1016\/j.ejphar.2021.173890_bib56","series-title":"Actemra (tocilizumab) Prescribing Information","author":"Genentech","year":"2017"},{"key":"10.1016\/j.ejphar.2021.173890_bib57","doi-asserted-by":"crossref","first-page":"104362","DOI":"10.1016\/j.jcv.2020.104362","article-title":"Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past","volume":"127","author":"Giannis","year":"2020","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.ejphar.2021.173890_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.01307","article-title":"The potential role of heparin in patients with COVID-19: beyond the anticoagulant effect. A review","volume":"11","author":"Gozzo","year":"2020","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.ejphar.2021.173890_bib59","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2021.173890_bib60","article-title":"Sarilumab use in severe SARS-CoV-2 pneumonia","volume":"27","author":"Gremese","year":"2020","journal-title":"Clin. Med."},{"key":"10.1016\/j.ejphar.2021.173890_bib61","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(99)11433-8","article-title":"Influenza virus neuraminidase inhibitors","volume":"355","author":"Gubareva","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2021.173890_bib62","series-title":"Controlled Randomized Clinical Trial on Using Ivermectin with Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq","author":"Hashim","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib63","article-title":"Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment","volume":"12","author":"Hassan","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.ejphar.2021.173890_bib64","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/v10040184","article-title":"Arbidol (Umifenovir): a broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses","volume":"10","author":"Haviernik","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.ejphar.2021.173890_bib65","series-title":"Molecular Mechanism of SARS-CoV-2 Cell Entry Inhibition via TMPRSS2 by Camostat and Nafamostat Mesylate","author":"Hempel","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib66","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s13054-020-03227-4","article-title":"Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients","volume":"24","author":"Hifumi","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejphar.2021.173890_bib67","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/phar.2403","article-title":"Delayed initiation of remdesivir in a COVID\u201019 positive patient","volume":"40","author":"Hillaker","year":"2020","journal-title":"Pharmacother"},{"key":"10.1016\/j.ejphar.2021.173890_bib68","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"171","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2021.173890_bib69","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2021.173890_bib70","series-title":"Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: preliminary Results from a Multi-centre, Randomized, Controlled Trial","author":"Horby","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib71","first-page":"1","article-title":"Dexamethasone in hospitalized patients with COVID-19 - preliminary report","author":"Horby","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2021.173890_bib72","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2021.173890_bib73","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"The Lancet Rheumatol"},{"key":"10.1016\/j.ejphar.2021.173890_bib74","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02185-18","article-title":"Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses","volume":"93","author":"Hulseberg","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2021.173890_bib75","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 tria","volume":"30","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2021.173890_bib76","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ijid.2020.05.072","article-title":"Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy","volume":"96","author":"Jang","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejphar.2021.173890_bib77","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1136\/gutjnl-2020-321852","article-title":"Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series","volume":"69","author":"Janowitz","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2021.173890_bib78","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jmii.2020.03.034","article-title":"Treatment options for COVID-19: the reality and challenges","volume":"53","author":"Jean","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"2","key":"10.1016\/j.ejphar.2021.173890_bib79","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1073\/pnas.1617020114","article-title":"Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol","volume":"114","author":"Kadam","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2021.173890_bib80","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1021\/jm9704098","article-title":"Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease","volume":"40","author":"Kaldor","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2021.173890_bib81","doi-asserted-by":"crossref","first-page":"104874","DOI":"10.1016\/j.phrs.2020.104874","article-title":"Nitazoxanide\/Azithromycin combination for COVID-19: a suggested new protocol for COVID-19 early management","volume":"157","author":"Kelleni","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.ejphar.2021.173890_bib82","doi-asserted-by":"crossref","first-page":"489","DOI":"10.12788\/jhm.3497","article-title":"Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19","volume":"15","author":"Keller","year":"2020","journal-title":"J. Hosp. Med."},{"key":"10.1016\/j.ejphar.2021.173890_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01248","article-title":"Thalidomide-revisited: are COVID-19 patients going to be the latest victims of yet another theoretical drug-repurposing?","volume":"11","author":"Khalil","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2021.173890_bib84","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jmv.25798","article-title":"Novel coronavirus treatment with ribavirin: groundwork for evaluation concerning COVID\u201019","volume":"92","author":"Khalili","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejphar.2021.173890_bib85","article-title":"Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach","volume":"1\u201310","author":"Khan","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"8","key":"10.1016\/j.ejphar.2021.173890_bib86","first-page":"1062","article-title":"Remdesivir for COVID-19 treatment: mechanism OF action, synthesis, and clinical trials","volume":"9","author":"Khanal","year":"2020","journal-title":"J Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejphar.2021.173890_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30160-0","article-title":"Anakinra in COVID-19: important considerations for clinical trials","author":"King","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.ejphar.2021.173890_bib88","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ejphar.2021.173890_bib89","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ijid.2020.08.024","article-title":"Impact of tocilizumab on mortality and\/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients","volume":"99","author":"Klopfensteina","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejphar.2021.173890_bib90","doi-asserted-by":"crossref","first-page":"105933","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favour of remdesivir for treating SARS-CoV-2 infections","volume":"55","author":"Ko","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2021.173890_bib91","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus\u2013induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2021.173890_bib33","unstructured":"iving guidance. 2020. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Corticosteroids-2020.1.."},{"key":"10.1016\/j.ejphar.2021.173890_bib92","doi-asserted-by":"crossref","unstructured":"La Scola, B., Le Bideau, M., Andreani, J., Hoang, V.T., Grimaldier, C., Colson, P., Gautret, P., Raoult, D., Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur. J. Clin. Microbiol. Infect. Dis.. 39, 1059-1061. https:\/\/doi.org\/10.1007\/s10096-020-03913-9.","DOI":"10.1007\/s10096-020-03913-9"},{"key":"10.1016\/j.ejphar.2021.173890_bib93","doi-asserted-by":"crossref","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2021.173890_bib94","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40121-020-00332-3","article-title":"Efficacy evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with NonSevere COVID-19 pneumonia: a retrospective cohort study","volume":"9","author":"Li","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.ejphar.2021.173890_bib95","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41440-020-0433-1","article-title":"Antihypertensive treatment with ACEI\/ARB of patients with COVID-19 complicated by hypertension","volume":"43","author":"Li","year":"2020","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2021.173890_bib96","article-title":"Potential antiviral therapeutics for 2019 novel coronavirus","volume":"43","author":"Li","year":"2020","journal-title":"Zhonghua Jiehe He Huxi Zazhi"},{"issue":"1","key":"10.1016\/j.ejphar.2021.173890_bib97","first-page":"105","article-title":"Efficacy and safety of Lopinavir\/Ritonavir or Arbidol in adult patients with mild\/moderate COVID-19: An exploratory randomized controlled trial","volume":"1","author":"Li","year":"2020","journal-title":"Med (N Y)"},{"issue":"7","key":"10.1016\/j.ejphar.2021.173890_bib98","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cmi.2020.04.026","article-title":"Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study","volume":"26","author":"Lian","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejphar.2021.173890_bib99","article-title":"Case of the index patient who caused tertiary transmission of Coronavirus disease 2019 in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J. Kor. Med. Sci."},{"key":"10.1016\/j.ejphar.2021.173890_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-019-0132-8","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.ejphar.2021.173890_bib101","article-title":"Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province","volume":"133","author":"Liu","year":"2020","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.ejphar.2021.173890_bib102","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01410-20","article-title":"Type I interferon susceptibility distinguishes SARSCoV-2 from SARS-CoV","author":"Lokugamage","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2021.173890_bib103","unstructured":"Losartan for Patients With COVID-19 Requiring Hospitalization. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04312009."},{"key":"10.1016\/j.ejphar.2021.173890_bib104","unstructured":"Losartan for patients with COVID-19 not requiring hospitalization.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04311177."},{"key":"10.1016\/j.ejphar.2021.173890_bib105","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID\u201019: a single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejphar.2021.173890_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43141-020-00055-5","article-title":"Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?","volume":"18","author":"Mahmoud","year":"2020","journal-title":"J Genet Eng Biotechnol"},{"key":"10.1016\/j.ejphar.2021.173890_bib107","doi-asserted-by":"crossref","first-page":"104811","DOI":"10.1016\/j.antiviral.2020.104811","article-title":"Potent antiviral activities of Type I interferons to SARS-CoV-2 infection","volume":"179","author":"Mantlo","year":"2020","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.ejphar.2021.173890_bib108","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2147\/COPD.S681","article-title":"Role of macrolide therapy in chronic obstructive pulmonary disease","volume":"3","author":"Martinez","year":"2008","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.ejphar.2021.173890_bib109","series-title":"The Inhaled Corticosteroid Ciclesonide Blocks Coronavirus RNA Replication by Targeting Viral NSP15","author":"Matsuyama","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib110","series-title":"An Experimental Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in an Epidemic Area","author":"Meng","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib111","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.annonc.2020.03.300","article-title":"Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report","volume":"31","author":"Michot","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejphar.2021.173890_bib112","first-page":"1","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial","author":"Monk","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ejphar.2021.173890_bib113","article-title":"Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19","volume":"1\u20136","author":"Muralidharan","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejphar.2021.173890_bib114","article-title":"The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections","volume":"6","author":"Musarrat","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejphar.2021.173890_bib115","article-title":"Corticosteroid use for 2019-nCoV infection: a double-edged sword","volume":"1\u20136","author":"Nasim","year":"2020","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"10.1016\/j.ejphar.2021.173890_bib116","unstructured":"National Institute of Allergy and Infectious Diseases. Statement\u2014NIH-sponsored ACTIV-3 trial closes LY-CoV555 sub-study. https:\/\/www.niaid.nih.gov\/news-events\/statement-nih-sponsored-activ-3-trial-closes-ly-cov555-sub-study."},{"key":"10.1016\/j.ejphar.2021.173890_bib117","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/jac\/dkz524","article-title":"Safety of high-dose ivermectin: a systematic review and meta-analysis","volume":"75","author":"Navarro","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2021.173890_bib118","unstructured":"nlmhttps:\/\/pubchem.ncbi.nlm.nih.gov\/."},{"key":"10.1016\/j.ejphar.2021.173890_bib119","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2217\/fvl-2018-0166","article-title":"Ribavirin: pharmacology, multiple modes of action and possible future perspectives","volume":"14","author":"Nystr\u00f6m","year":"2019","journal-title":"Future Virol."},{"key":"10.1016\/j.ejphar.2021.173890_bib120","series-title":"Flu and HIV Drugs Show Efficacy against Coronavirus","author":"Offord","year":"2020"},{"issue":"5","key":"10.1016\/j.ejphar.2021.173890_bib121","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jmii.2020.05.014","article-title":"Lopinavir\/ritonavir use in Covid-19 infection: is it completely non-beneficial?","volume":"53","author":"Owa","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.ejphar.2021.173890_bib122","first-page":"1410","article-title":"Weak induction of interferon expression by SARS-CoV-2 supports clinical trials of interferon Lambda to treat early COVID-19","volume":"71","author":"O'Brien","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejphar.2021.173890_bib123","series-title":"Efficacy and Tolerability of Bevacizumab 2 in Patients with Severe Covid -19","author":"Pang","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib124","article-title":"Peptide-like and small-molecule inhibitors against Covid-19","volume":"1\u201310","author":"Pant","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejphar.2021.173890_bib125","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","article-title":"Azithromycin: mechanisms of action and their relevance for clinical applications","volume":"143","author":"Parnham","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2021.173890_bib126","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/j.jaad.2020.04.017","article-title":"Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and\/or treatment?","volume":"82","author":"Patr\u00ec","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2021.173890_bib127","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/clinids\/12.6.1139","article-title":"Molecular mechanisms of action of ribavirin","volume":"12","author":"Patterson","year":"1990","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.ejphar.2021.173890_bib128","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/B978-0-12-803109-4.00017-9","article-title":"Family Coronaviridae","author":"Payne","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.ejphar.2021.173890_bib129","first-page":"52","article-title":"Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19","volume":"6","author":"Pepperrell","year":"2020","journal-title":"J Vir Erad"},{"key":"10.1016\/j.ejphar.2021.173890_bib130","article-title":"Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses","volume":"93","author":"Polyak","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2021.173890_bib131","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14740338.2017.1269168","article-title":"Hydroxychloroquine in systemic lupus erythematosus (SLE)","volume":"16","author":"Ponticelli","year":"2017","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejphar.2021.173890_bib132","doi-asserted-by":"crossref","first-page":"104257","DOI":"10.1016\/j.bioorg.2020.104257","article-title":"Is oseltamivir suitable for fighting against COVID-19: in silico assessment, in vitro and retrospective study","volume":"104","author":"Qi","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejphar.2021.173890_bib133","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.chest.2020.04.024","article-title":"Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: a cautionary case report","volume":"158","author":"Radbel","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2021.173890_bib134","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids: mechanisms of action in health and disease","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheum. Dis. Clin."},{"key":"10.1016\/j.ejphar.2021.173890_bib135","unstructured":"Rhoades, A., 2020. https:\/\/www.fda.gov\/media\/137564\/download."},{"key":"10.1016\/j.ejphar.2021.173890_bib136","doi-asserted-by":"crossref","first-page":"104826","DOI":"10.1016\/j.phrs.2020.104826","article-title":"Darunavir does not prevent SARS-CoV-2 infection in HIV patients","volume":"157","author":"Riva","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2021.173890_bib137","article-title":"Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo controlled trial","author":"Rocco","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2021.173890_bib138","unstructured":"Romark initiates new phase 3 clinical trial of NT-300 for the treatment of COVID-19. Romark Pharmaceuticals. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04359680."},{"key":"10.1016\/j.ejphar.2021.173890_bib139","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.26633\/RPSP.2020.40","article-title":"Clinical trials on drug repositioning for COVID-19 treatment","volume":"44","author":"Rosa","year":"2020","journal-title":"Rev. Panam. Salud P\u00fablic"},{"key":"10.1016\/j.ejphar.2021.173890_bib140","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejphar.2021.173890_bib141","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.arcmed.2020.05.001","article-title":"Probable molecular mechanism of remdesivir for the treatment of COVID-19: need to know more","volume":"51","author":"Saha","year":"2020","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.ejphar.2021.173890_bib142","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virol.2004.08.011","article-title":"Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)","volume":"329","author":"Sainz","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.ejphar.2021.173890_bib143","doi-asserted-by":"crossref","first-page":"104791","DOI":"10.1016\/j.antiviral.2020.104791","article-title":"Type 1 interferons as a potential treatment against COVID-19","volume":"178","author":"Sallard","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2021.173890_bib144","series-title":"Efficacy of Famotidine for COVID-19: A Systematic Review and Meta-Analysis","author":"Sethia","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib145","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2021.173890_bib146","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12985-020-01412-z","article-title":"Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis","volume":"17","author":"Shrestha","year":"2020","journal-title":"Virol. J."},{"key":"10.1016\/j.ejphar.2021.173890_bib147","article-title":"Hydroxychloroquine for the treatment and prophylaxis of COVID-19: the journey so far and the road ahead","volume":"173717","author":"Singh","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.173890_bib148","first-page":"1120","article-title":"Systematic and statistical review of coronavirus disease 19 treatment trials. SN Compr","volume":"2","author":"Siordia","year":"2020","journal-title":"Clin. Med."},{"key":"10.1016\/j.ejphar.2021.173890_bib149","doi-asserted-by":"crossref","first-page":"106080","DOI":"10.1016\/j.ijantimicag.2020.106080","article-title":"COVID-19 treatment: close to a cure?\u2013A rapid review of pharmacotherapies for the novel coronavirus","volume":"56","author":"Song","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2021.173890_bib150","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14656566.2018.1484901","article-title":"Darunavir for the treatment of HIV infection","volume":"19","author":"Spagnuolo","year":"2018","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2021.173890_bib151","doi-asserted-by":"crossref","first-page":"20246","DOI":"10.4414\/smw.2020.20246","article-title":"Benign COVID-19 in an immunocompromised cancer patient-the case of a married couple","volume":"150","author":"Spezzani","year":"2020","journal-title":"Swiss Med. Wkly."},{"issue":"13","key":"10.1016\/j.ejphar.2021.173890_bib152","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19 A meta-analysis","volume":"324","author":"Sterne","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2021.173890_bib153","series-title":"A Randomized Trial of Ivermectin-doxycycline and Hydroxychloroquine-azithromycin Therapy on COVID19 Patients. Research Square","author":"Taiub","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib154","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 en la inflamaci\u00f3n, la inmunidad, y la enfermedad","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"10.1016\/j.ejphar.2021.173890_bib155","first-page":"218","article-title":"Mechanism of action of ribavirin in the treatment of chronic hepatitis C","volume":"3","author":"Te","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2021.173890_bib156","unstructured":"The efficacy and safety of thalidomide combined with low-dose hormones in the treatment of severe Covid-19. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04273581?term=NCT04273581&draw=2&rank=1."},{"key":"10.1016\/j.ejphar.2021.173890_bib157","unstructured":"The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (Covid-19) pneumonia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04273529?term=NCT04273529&draw=2&rank=1.."},{"key":"10.1016\/j.ejphar.2021.173890_bib158","unstructured":"To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04327388.."},{"key":"10.1016\/j.ejphar.2021.173890_bib159","unstructured":"Tocilizumab in COVID-19 pneumonia (TOCIVID-19) (TOCIVID-19). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04317092.."},{"key":"10.1016\/j.ejphar.2021.173890_bib160","unstructured":"Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04315480."},{"key":"10.1016\/j.ejphar.2021.173890_bib161","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.34172\/jrip.2020.19","article-title":"COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment","volume":"9","author":"Tolouian","year":"2020","journal-title":"J. Ren. Inj. Prev."},{"issue":"3","key":"10.1016\/j.ejphar.2021.173890_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106114","article-title":"Ribavirin therapy for severe COVID-19: a retrospective cohort study","volume":"56","author":"Tong","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2021.173890_bib163","first-page":"2657","article-title":"A review of SARS-CoV-2 and the ongoing clinical trials","volume":"21","author":"Tu","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejphar.2021.173890_bib164","unstructured":"usphttps:\/\/www.usp.org\/."},{"key":"10.1016\/j.ejphar.2021.173890_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110668","article-title":"Insights into antiviral mechanisms of remdesivir, lopinavir\/ritonavir and chloroquine\/hydroxychloroquine affecting the new SARS-CoV-2","author":"Uzunova","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2021.173890_bib166","series-title":"Kinins and Cytokines in COVID-19: a Comprehensive Pathophysiological Approach","author":"Van de Veerdonk","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib167","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"10.1016\/j.ejphar.2021.173890_bib168","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2021.173890_bib169","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","article-title":"Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro","volume":"7","author":"Wang","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ejphar.2021.173890_bib170","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2021.173890_bib171","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.ejphar.2021.173890_bib172","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ejphar.2021.173890_bib173","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2021.173890_bib174","series-title":"Early, Low-dose and Short-term Application of Corticosteroid Treatment in Patients with Severe COVID-19 Pneumonia: single-Center Experience from Wuhan, China","author":"Wang","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib175","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dki018","article-title":"Oseltamivir (Tamiflu\u00ae) and its potential for use in the event of an influenza pandemic","volume":"55","author":"Ward","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2021.173890_bib176","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejphar.2021.173890_bib177","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/cid\/ciaa199","article-title":"Clinical characteristics of imported cases of COVID-19 in jiangsu province: a multicenter descriptive study","volume":"71","author":"Wu","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejphar.2021.173890_bib178","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"17","author":"Xu","year":"2020","journal-title":"Pnas"},{"key":"10.1016\/j.ejphar.2021.173890_bib179","series-title":"Nelfinavir was Predicted to be a Potential Inhibitor of 2019-nCov Main Protease by an Integrative Approach combining Homology Modelling, Molecular Docking and Binding Free Energy Calculation","author":"Xu","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib180","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bbrc.2004.04.083","article-title":"HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus","volume":"318","author":"Yamamoto","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2021.173890_bib181","series-title":"Nelfinavir Inhibits Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in vitro","author":"Yamamoto","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib182","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/jmv.25729","article-title":"A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus\u2014a possible reference for coronavirus disease\u201019 treatment option","volume":"92","author":"Yao","year":"2020","journal-title":"J Med. Virol."},{"key":"10.1016\/j.ejphar.2021.173890_bib183","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejphar.2021.173890_bib184","article-title":"The place for remdesivir in COVID-19 treatment","volume":"21","author":"Young","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejphar.2021.173890_bib185","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1017\/ice.2020.80","article-title":"A potential protective role of losartan against coronavirus-induced lung damage","volume":"41","author":"Zeinalian","year":"2020","journal-title":"Infect. Control Hosp. Epidemiol."},{"issue":"9","key":"10.1016\/j.ejphar.2021.173890_bib186","doi-asserted-by":"crossref","DOI":"10.5694\/mja2.50577","article-title":"Corticosteroid treatment of patients with coronavirus disease 2019 (COVID\u201019)","volume":"212","author":"Zha","year":"2020","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.ejphar.2021.173890_bib187","series-title":"Binding Mechanism of Remdesivir to SARS-CoV-2 RNA Dependent RNA Polymerase","author":"Zhang","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2021.173890_bib189","series-title":"Teicoplanin Potently Blocks the Cell Entry of 2019-nCoV","author":"Zhang","year":"2020"},{"key":"10.1016\/j.ejphar.2021.173890_bib190","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/bloodadvances.2020001907","article-title":"First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejphar.2021.173890_bib191","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/CM9.0000000000000791","article-title":"Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial","volume":"133","author":"Zhou","year":"2020","journal-title":"Chin Med J (Engl)."},{"key":"10.1016\/j.ejphar.2021.173890_bib192","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3389\/fimmu.2020.01061","article-title":"Interferon-a2b treatment for COVID-19","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:48:41Z","timestamp":1757976521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":192,"alternative-id":["S0014299921000431"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.173890","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of potential suggested drugs for coronavirus disease (COVID-19) treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.173890","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173890"}}